Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.30 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31405448 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2EGFRCRHBP | |
| SCHEMBL1294228 | 0.80 | TDP1 (0.45) | ALDH1A1KDM4ECRHBPCRHR2PIK3CD | |
| SCHEMBL30082286 | 0.78 | CRHBP (0.35) | ALDH1A1CRHBPCRHR2PIK3CDTDP1 | |
| SCHEMBL22057382 | 0.78 | CYP1A2 (0.41) | ALDH1A1KDM4ESMN1; SMN2EGFRRPS6KA5 | |
| SCHEMBL24885772 | 0.74 | EGFR (0.38) | ALDH1A1KDM4EEGFR | |
| SCHEMBL20660757 | 0.74 | CCNE2 (0.32) | ALDH1A1 | |
| SCHEMBL24558656 | 0.74 | MEN1 (0.45) | ALDH1A1KDM4ESMN1; SMN2TDP1NPC1 | |
| SCHEMBL20660740 | 0.74 | NT5E (0.40) | ALDH1A1KDM4ESMN1; SMN2EGFRPIK3CD | |
| SCHEMBL24558654 | 0.74 | SMN1; SMN2 (0.36) | ALDH1A1KDM4ESMN1; SMN2EGFRNPC1 | |
| SCHEMBL4119455 | 0.71 | EGFR (0.43) | ALDH1A1EGFRCRHBPCRHR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339444-A1 | Methods and Compositions for Treating Fatty Liver and Viral Infections | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4525853-A1 | METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-11-14 | — | — | US | disclosed |
| US-20240270759-A1 | Preparation of SHP2 phosphatase inhibitors and its applications | YA THERAPEUTICS INC (CN) | 2024-08-15 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023225324-A1 | METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225324-A1 | METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2323986-A2 | HETOEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2321299-A2 | PYRIDONS AS PDK1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | ALDH1A1 4636/4885KDM4E 2695/4885SMN1; SMN2 2475/4885 |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | PDK2, PDK4, CCNH | ALDH1A1 816/4885KDM4E 1191/4885SMN1; SMN2 4087/4885 |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ALDH1A1 4630/4885KDM4E 3828/4885SMN1; SMN2 670/4885 |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | PDK1, PDK2, PDK4 | ALDH1A1 1546/4885KDM4E 588/4885SMN1; SMN2 3260/4885 |
| US-20250339444-A1 | Methods and Compositions for Treating Fatty Liver and Viral Infections | FABP1, FABP4, LIPC | ALDH1A1 3505/4885KDM4E 558/4885SMN1; SMN2 2956/4885 |
| US-20240270759-A1 | Preparation of SHP2 phosphatase inhibitors and its applications | PTPN2, PTPN22, PTPN5 | ALDH1A1 2493/4885KDM4E 861/4885SMN1; SMN2 826/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | ALDH1A1 4542/4885KDM4E 4410/4885SMN1; SMN2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.